12/4/2020  5:35:06 PM Chg. +0.28 Volume Bid12/4/2020 Ask5:35:09 PM Market Capitalization Dividend Y. P/E Ratio
53.80EUR +0.52% 100,987
Turnover: 5.41 mill.
-Bid Size: - -Ask Size: - 2.93 bill.EUR 1.47% 37.99

Business description

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in the first half-year 2018.

Management board & Supervisory board

Dr. Hans-Georg Feldmeier
Management board
Hilde Neumeyer, Dr. Jürgen Ott, Karin Samusch
Supervisory board
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz

Company data

Name: Dermapharm Holding SE
Address: Lil-Dagover-Ring 7,D-82031 Grünwald
Phone: +49-89-64186-0
Fax: +49-89-64186-130
E-mail: -
Internet: ir.dermapharm.de/index.php
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: -
IPO date: 2/9/2018

Investor relations

Name: Britta Hamberger
IR phone: +49-89-64186-233
IR Fax: +49-89-64186-165
IR e-mail: ir@dermapharm.com

Main Shareholders

Themis Beteiligungs-AG